Johnson & Johnson's most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $94.00 short put and a strike $89.00 long put offers a potential 6.16% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $94.00 by expiration. The full premium credit of $0.29 would be kept by the premium seller. The risk of $4.71 would be incurred if the stock dropped below the $89.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.
The RSI indicator is at 72.4 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
Pfizer Inc.: Big Pharma Checkup for 2014
Sat, 11 Jan 2014 23:54:30 GMT
Motley Fool – Pfizer Inc.'s (PFE) cost cuts and newly approved drugs may position it for profit growth over the long haul.
Can Eli Lilly & Co. Quickly Stop Stumbling in 2014?
Sat, 11 Jan 2014 23:26:09 GMT
Motley Fool – Eli Lilly recently released a 2014 revenue forecast below levels not seen since early 2008. Find out if its five compounds under review at the FDA can stop the bleeding.
The Dow's Biggest Losers Last Week
Sat, 11 Jan 2014 22:20:43 GMT
Motley Fool – An in-depth look at what caused a few stocks to fall.
The Top Stocks on the Dow This Week
Sat, 11 Jan 2014 18:02:34 GMT
Motley Fool – The Dow fell slightly this week but Johnson & Johnson, Boeing, and Cisco had much better weeks.
Will a DOJ Subpoena Derail Aegerion's Growth in 2014?
Sat, 11 Jan 2014 17:47:38 GMT
Motley Fool – Orphan drug maker Aegerion recently plunged on the announcement that the DOJ had started investigating its marketing practices. Does this drop represent a rare buying opportunity for the high-flying stock, …
Also on Market Tamer…
Follow Us on Facebook